HomeCompareNIABY vs JNJ

NIABY vs JNJ: Dividend Comparison 2026

NIABY yields 0.77% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $10.1K in total portfolio value· pulled ahead in Year 5
10 years
NIABY
NIABY
● Live price
0.77%
Share price
$4.03
Annual div
$0.03
5Y div CAGR
-17.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.1K
Annual income
$11.01
Full NIABY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — NIABY vs JNJ

📍 JNJ pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNIABYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NIABY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NIABY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NIABY
Annual income on $10K today (after 15% tax)
$65.75/yr
After 10yr DRIP, annual income (after tax)
$9.36/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,976.63/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NIABY + JNJ for your $10,000?

NIABY: 50%JNJ: 50%
100% JNJ50/50100% NIABY
Portfolio after 10yr
$25.2K
Annual income
$2,350.21/yr
Blended yield
9.32%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

NIABY
No analyst data
Altman Z
2.3
Piotroski
8/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NIABY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNIABYJNJ
Forward yield0.77%2.13%
Annual dividend / share$0.03$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-17.9%28%
Portfolio after 10y$20.1K$30.3K
Annual income after 10y$11.01$4,689.40
Total dividends collected$309.00$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NIABY vs JNJ ($10,000, DRIP)

YearNIABY PortfolioNIABY Income/yrJNJ PortfolioJNJ Income/yrGap
1$10,764$63.50$10,592$272.30+$172.00NIABY
2$11,569$52.45$11,289$357.73+$280.00NIABY
3$12,423$43.25$12,123$472.89+$300.00NIABY
4$13,328$35.64$13,141$629.86+$187.00NIABY
5← crossover$14,290$29.34$14,408$846.81$118.00JNJ
6$15,314$24.13$16,021$1,151.60$707.00JNJ
7$16,406$19.85$18,122$1,588.22$1.7KJNJ
8$17,571$16.31$20,930$2,228.20$3.4KJNJ
9$18,814$13.41$24,792$3,191.91$6.0KJNJ
10$20,142$11.01$30,274$4,689.40$10.1KJNJ

NIABY vs JNJ: Complete Analysis 2026

NIABYStock

NIBE Industrier AB (publ), together with its subsidiaries, develops, manufactures, markets, and sells various energy-efficient solutions for indoor climate comfort, and components and solutions for intelligent heating and control in Nordic countries, rest of Europe, North America, and internationally. The company operates through three business areas: NIBE Climate Solutions, NIBE Element, and NIBE Stoves. The NIBE Climate Solutions business area offers indoor climate comfort products, such as heat pumps, ventilation products and air conditioning, climate control systems, water heaters and accumulator tanks, district heating products, PV panels, domestic boilers, commercial washing machines, and tumble dryers for homes, apartment blocks, and commercial properties. The NIBE Element business area provides various components and solutions for heating and control, which include tubular, aluminum, foil, thick film, PTC, high-power, and ceramic elements, as well as open spirals and tapes, heating cables and jackets, vacuum brazing, heat pump technology, resistors, heat exchangers, temperature sensors, flexible hoses, and control equipment to domestic and household appliances; commercial products and professional kitchens; energy; transport; advanced technology; medicine; and aviation sectors, as well as industrial projects sectors. The NIBE Stoves business area offers free-standing, wood-burning, gas, and electric stoves; heat-retaining products; and chimney systems, as well as accessories. NIBE Industrier AB (publ) was founded in 1949 and is headquartered in Markaryd, Sweden.

Full NIABY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this NIABY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NIABY vs SCHDNIABY vs JEPINIABY vs ONIABY vs KONIABY vs MAINNIABY vs ABBVNIABY vs MRKNIABY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.